{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:39:19Z","timestamp":1789007959760,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":3783,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HI13C-1602-010013"],"award-info":[{"award-number":["HI13C-1602-010013"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Otolaryngology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.amjoto.2014.04.014","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T14:53:36Z","timestamp":1399388016000},"page":"664-668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Infliximab for refractory oral ulcers"],"prefix":"10.1016","volume":"35","author":[{"given":"Hee Jung","family":"Ryu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Ryoung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Joo","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjoto.2014.04.014_bb0005","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1600-0714.2012.01134.x","article-title":"Recurrent aphthous stomatitis: a review","volume":"41","author":"Chavan","year":"2012","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.14219\/jada.archive.2003.0134","article-title":"The diagnosis and management of recurrent aphthous stomatitis: a consensus approach","volume":"134","author":"Scully","year":"2003","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1601-0825.2005.01143.x","article-title":"Mucosal disease series. Number VI. Recurrent aphthous stomatitis","volume":"12","author":"Jurge","year":"2006","journal-title":"Oral Dis"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0020","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.ebd.6400901","article-title":"Inconclusive evidence on systemic treatments for recurrent aphthous stomatitis","volume":"13","author":"Spivakovsky","year":"2012","journal-title":"Evid Based Dent"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1468-3083.2011.04041.x","article-title":"Efficacy of tumour necrosis factor-alpha antagonists in aphthous ulceration: review of published individual patient data","volume":"26","author":"O'Neill","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0901-5027(00)80057-0","article-title":"Increased density of lymphocytes bearing gamma\/delta T-cell receptors in recurrent aphthous ulceration (RAU)","volume":"29","author":"Natah","year":"2000","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.imlet.2005.01.002","article-title":"Predominance of type 1 cytokines and decreased number of CD4(+)CD25(+high) T regulatory cells in peripheral blood of patients with recurrent aphthous ulcerations","volume":"99","author":"Lewkowicz","year":"2005","journal-title":"Immunol Lett"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0040","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/03009740600905380","article-title":"Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Beh\u00e7et's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD","volume":"35","author":"Dalghous","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0045","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0722.2005.00216.x","article-title":"Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters","volume":"113","author":"Lima","year":"2005","journal-title":"Eur J Oral Sci"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0055","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0060","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/ard.2008.087957","article-title":"Management of Beh\u00e7et disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Beh\u00e7et disease","volume":"68","author":"Hatemi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0065","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0070","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaad.2004.11.031","article-title":"A case of mucocutaneous Beh\u00e7et's disease responding to etanercept","volume":"52","author":"Sommer","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0075","first-page":"729","article-title":"Successful treatment of resistant Beh\u00e7et's disease with etanercept","volume":"23","author":"Atzeni","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0080","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard.2006.064279","article-title":"Adalimumab: a new modality for Beh\u00e7et's disease?","volume":"66","author":"van Laar","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0085","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/rheumatology\/kes130","article-title":"Adalimumab for the treatment of Beh\u00e7et's disease: experience in 19 patients","volume":"51","author":"Perra","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0090","first-page":"S99","article-title":"Infliximab for the treatment of resistant oral ulcers in Beh\u00e7et's disease: a case report and review of the literature","volume":"25","author":"Almoznino","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.amjoto.2014.04.014_bb0095","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00296-009-1276-x","article-title":"Late response to anti-TNF-alpha therapy in refractory mucocutaneous lesions of Beh\u00e7et's disease","volume":"31","author":"Aikawa","year":"2011","journal-title":"Rheumatol Int"}],"container-title":["American Journal of Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070914001082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070914001082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:57:26Z","timestamp":1759294646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196070914001082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0196070914001082"],"URL":"https:\/\/doi.org\/10.1016\/j.amjoto.2014.04.014","relation":{},"ISSN":["0196-0709"],"issn-type":[{"value":"0196-0709","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab for refractory oral ulcers","name":"articletitle","label":"Article Title"},{"value":"American Journal of Otolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjoto.2014.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}